Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy
Conclusion: Increased fat reserves assessed by BMI, CRP, LDH, and interval between initial diagnosis and RLT, but not CT-derived body composition parameters, were relevant predictors for OS. As BMI can be altered, future research should investigate whether a high-calorie diet before or during PSMA RLT may improve OS. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Hartrampf, P. E., Mihatsch, P. W., Seitz, A. K., Solnes, L. B., Rowe, S. P., Pomper, M. G., Kubler, H., Bley, T. A., Buck, A. K., Werner, R. A. Tags: Clinical Investigations Source Type: research
[177Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naive Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis
Conclusion: mCRPC patients with no prior taxanes had significantly better outcomes after [177Lu]Lu-PSMA-RLT than did taxane-treated patients. Further trials evaluating [177Lu]Lu-PSMA-RLT in the taxane-naïve setting are now required. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Satapathy, S., Sahoo, R. K., Bal, C. Tags: Clinical Investigations Source Type: research
A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy
Conclusion: Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for 68Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Kuo, P. H., Yoo, D. C., Avery, R., Seltzer, M., Calais, J., Nagarajah, J., Weber, W. A., Fendler, W. P., Hofman, M. S., Krause, B. J., Brackman, M., Kpamegan, E., Ghebremariam, S., Benson, T., Catafau, A. M., Kendi, A. T. Tags: Clinical Investigations Source Type: research
The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy
Conclusion: Patient selection for PSMA RLT according to the inclusion criteria of TheraP led to a better treatment response and outcome in our preselected patient cohort. However, a relevant number of patients not fulfilling these criteria also showed substantial rates of response. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Karimzadeh, A., Heck, M., Tauber, R., Solaris, E., Nekolla, S., Knorr, K., Haller, B., DAlessandria, C., Weber, W. A., Eiber, M., Rauscher, I. Tags: Clinical Investigations Source Type: research
Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years
Conclusion: [177Lu]-PSMA-I&T RLT in mCRPC patients at least 80 y old is safe and effective, comparable to previously published data on non–age-selected cohorts with a low rate of high-grade toxicities. Chemotherapy-naïve patients showed a better and longer response to therapy than taxane-pretreated patients. [177Lu]-PSMA RLT seems to be a meaningful treatment option for older patients. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Tauber, R., Knorr, K., Retz, M., Rauscher, I., Grigorascu, S., Hansen, K., DAlessandria, C., Wester, H.-J., Gschwend, J., Weber, W., Eiber, M., Langbein, T. Tags: Clinical Investigations Source Type: research
The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer
Conclusion: Given that metastatic disease was observed in nearly 1 in 10 men with newly diagnosed unfavorable intermediate-risk PCa, PSMA PET/CT is considered to be of diagnostic value within this population. Further stratification using the radiologic tumor stage and the percentage of positive prostate biopsies could aid in identifying those patients at risk of having metastatic disease on PSMA PET/CT. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Hagens, M. J., Luining, W. I., Jager, A., Donswijk, M. L., Cheung, Z., Wondergem, M., Oprea-Lager, D. E., Vis, A. N., van Leeuwen, P. J., van der Poel, H. G. Tags: Clinical Investigations Source Type: research
Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial
Conclusion: We conclude that [68Ga]FAPI-46 PET/CT can accurately differentiate malignant from benign pancreatic lesions deemed equivocal by standard-of-care imaging. This trial will therefore continue to recruit a total of 120 patients to reach those 38 equivocal observations needed for sufficient statistical power. On the basis of our findings, we propose that [68Ga]FAPI-46 PET/CT not only can be clinically applied as a complement but also could become a necessary tool when standard-of-care imaging is inconclusive. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Rasinski, P., af Buren, S., Holstensson, M., Nilsson, T., Loizou, L., Tran, T. A., Sparrelid, E., Lohr, J. M., Axelsson, R. Tags: Clinical Investigations Source Type: research
Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
Conclusion: [18F]FAPI-74 PET showed higher uptake and detection rates in primary and metastatic lesions than did [18F]FDG PET. [18F]FAPI-74 PET is a promising novel diagnostic modality for various tumors, especially for precise staging before treatment, including characterization of tumor lesions before surgery. Moreover, 18F-labeled FAPI ligand might serve a higher demand in clinical care in the future. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Watabe, T., Naka, S., Tatsumi, M., Kamiya, T., Kimura, T., Shintani, Y., Abe, K., Miyake, T., Shimazu, K., Kobayashi, S., Kurokawa, Y., Eguchi, H., Doki, Y., Inohara, H., Kato, H., Mori, Y., Cardinale, J., Giesel, F. L. Tags: Clinical Investigations Source Type: research
Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
Conclusion: The diagnostic performance of FAPI PET/CT is superior to that of [18F]FDG in the detection of primary, nodal, and distant metastases. However, further studies are needed to better evaluate its utility and indication in specific cancer types and clinical settings. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Wass, G., Clifford, K., Subramaniam, R. M. Tags: Clinical Investigations Source Type: research
Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin {alpha}v{beta}3 in Various Cancer Types
Conclusion: 68Ga-FAPI-RGD exhibited improved tumor uptake and TBR compared with 18F-FDG and 68Ga-FAPI PET/CT. This study demonstrated the safety and clinical feasibility of 68Ga-FAPI-RGD PET/CT for imaging of various types of cancer. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Zhao, L., Wen, X., Xu, W., Pang, Y., Sun, L., Wu, X., Xu, P., Zhang, J., Guo, Z., Lin, Q., Chen, X., Chen, H. Tags: Clinical Investigations Source Type: research
Pretargeting with Cucurbituril-Adamantane Host-Guest Pair in Xenograft Models
Conclusion: The CB7-Adma strategy is highly suitable for pretargeted PET. The exceptional stability of the pretargeting agents and the specific and high tumor uptake of the pretargeted adamantane radioligands provide great potential for the platform. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Jallinoja, V. I. J., Abbriano, C. H., Bhatt, K., Kaur, A., Schlyer, D. J., Yazaki, P. J., Carney, B. D., Houghton, J. L. Tags: Basic Science Investigations Source Type: research
Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors
Conclusion: The findings that metformin decreases cell-surface HER receptors and reduces antibody–tumor binding may have significant implications for the use of antibodies targeting these receptors in cancer treatment and molecular imaging. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Panikar, S. S., Keltee, N., Berry, N.-K., Shmuel, S., Fisher, Z. T., Brown, E., Zidel, A., Mabry, A., Pereira, P. M. R. Tags: FEATURED BASIC SCIENCE ARTICLE Source Type: research
SUVmax Above 20 in 18F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary
Conclusion: Our retrospective work shows that an SUVmax above 20 on 18F-FDG PET/CT at the initial diagnostic workup is a favorable prognostic factor in patients with CUP. This finding deserves further prospective studies for validation. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Zaun, G., Weber, M., Metzenmacher, M., Wiesweg, M., Hilser, T., Zaun, Y., Liffers, S., Pogorzelski, M., Virchow, I., Eberhardt, W., Theurer, S., Sabbah, T. A., Reissig, T. M., Stuschke, M., Kurten, C., Hussain, T., Lang, S., Kasper, S., Fendler, W. P., He Tags: Brief Communications Source Type: research
Evaluation of [68Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space
Conclusion: SSTR PET/MRI and MRI yielded similar accuracy for the detection of meningiomas of the skull base and intraorbital space. Here, sequential low-dose SSTR PET/CT might be helpful for the planning of radioligand therapy or radiotherapy. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Milosevic, A., Styczen, H., Grueneisen, J., Li, Y., Weber, M., Fendler, W. P., Kirchner, J., Damman, P., Wrede, K., Lazaridis, L., Glas, M., Guberina, M., Eckstein, A., Blau, T., Herrmann, K., Umutlu, L., Forsting, M., Deuschl, C., Schaarschmidt, B. Tags: Clinical Investigations Source Type: research
Molecular Imaging, Radiochemistry, and Environmental Pollutants
The worldwide proliferation of persistent environmental pollutants is accelerating at an alarming rate. Not surprisingly, many of these pollutants pose a risk to human health. In this review, we examine recent literature in which molecular imaging and radiochemistry have been harnessed to study environmental pollutants. Specifically, these techniques offer unique ways to interrogate the pharmacokinetic profiles and bioaccumulation patterns of pollutants at environmentally relevant concentrations, thereby helping to determine their potential health risks. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Delaney, S., Sebastiano, J., Zeglis, B. M., Keinanen, O. M. Tags: Focus on Molecular Imaging Source Type: research
